Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12009036rdf:typepubmed:Citationlld:pubmed
pubmed-article:12009036lifeskim:mentionsumls-concept:C0424295lld:lifeskim
pubmed-article:12009036lifeskim:mentionsumls-concept:C0034798lld:lifeskim
pubmed-article:12009036lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:12009036lifeskim:mentionsumls-concept:C0920647lld:lifeskim
pubmed-article:12009036lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:12009036lifeskim:mentionsumls-concept:C0047845lld:lifeskim
pubmed-article:12009036pubmed:issue2lld:pubmed
pubmed-article:12009036pubmed:dateCreated2002-5-14lld:pubmed
pubmed-article:12009036pubmed:abstractTextThis study was performed to investigate the effect of tetrahydroisoxazolopyridine (THIP), a GABAA agonist, on the morphine-induced hyperactivity, reverse tolerance and postsynaptic dopamine receptor supersensitivity in mice. A single administration of morphine induced hyperactivity in mice. However, the morphine-induced hyperactivity was inhibited dose-dependently by the administration of THIP (0.2, 0.4 and 0.8 mg/kg, i.p.). In contrast, daily administration of morphine resulted in a reverse tolerance to the hyperactivity caused by morphine (10 mg/kg, s.c.). THIP inhibited the development of reverse tolerance in the mice that had received the repeated same morphine (10 mg/kg, s.c.) doses. The postsynaptic dopamine receptor super-sensitivity, which was evidenced by the enhanced ambulatory activity after the administration of apomorphine (2 mg/kg, s.c.), also developed in the reverse tolerant mice. THIP also inhibited the development of the postsynaptic dopamine receptor supersensitivity induced by the chronic morphine administration. These results suggest that the hyperactivity, reverse tolerance and postsynaptic dopamine receptor supersensitivity induced by morphine can be inhibited activating the GABAA receptors.lld:pubmed
pubmed-article:12009036pubmed:languageenglld:pubmed
pubmed-article:12009036pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12009036pubmed:citationSubsetIMlld:pubmed
pubmed-article:12009036pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12009036pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12009036pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12009036pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12009036pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12009036pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12009036pubmed:statusMEDLINElld:pubmed
pubmed-article:12009036pubmed:monthAprlld:pubmed
pubmed-article:12009036pubmed:issn0253-6269lld:pubmed
pubmed-article:12009036pubmed:authorpubmed-author:YoonIn-SeupISlld:pubmed
pubmed-article:12009036pubmed:authorpubmed-author:ShinIm-ChulIClld:pubmed
pubmed-article:12009036pubmed:authorpubmed-author:HongJin-TaeJTlld:pubmed
pubmed-article:12009036pubmed:authorpubmed-author:LeeMyung-KooM...lld:pubmed
pubmed-article:12009036pubmed:authorpubmed-author:OhKi-WanKWlld:pubmed
pubmed-article:12009036pubmed:issnTypePrintlld:pubmed
pubmed-article:12009036pubmed:volume25lld:pubmed
pubmed-article:12009036pubmed:ownerNLMlld:pubmed
pubmed-article:12009036pubmed:authorsCompleteYlld:pubmed
pubmed-article:12009036pubmed:pagination202-7lld:pubmed
pubmed-article:12009036pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:12009036pubmed:meshHeadingpubmed-meshheading:12009036...lld:pubmed
pubmed-article:12009036pubmed:meshHeadingpubmed-meshheading:12009036...lld:pubmed
pubmed-article:12009036pubmed:meshHeadingpubmed-meshheading:12009036...lld:pubmed
pubmed-article:12009036pubmed:meshHeadingpubmed-meshheading:12009036...lld:pubmed
pubmed-article:12009036pubmed:meshHeadingpubmed-meshheading:12009036...lld:pubmed
pubmed-article:12009036pubmed:meshHeadingpubmed-meshheading:12009036...lld:pubmed
pubmed-article:12009036pubmed:meshHeadingpubmed-meshheading:12009036...lld:pubmed
pubmed-article:12009036pubmed:meshHeadingpubmed-meshheading:12009036...lld:pubmed
pubmed-article:12009036pubmed:meshHeadingpubmed-meshheading:12009036...lld:pubmed
pubmed-article:12009036pubmed:meshHeadingpubmed-meshheading:12009036...lld:pubmed
pubmed-article:12009036pubmed:meshHeadingpubmed-meshheading:12009036...lld:pubmed
pubmed-article:12009036pubmed:year2002lld:pubmed
pubmed-article:12009036pubmed:articleTitleInhibition of THIP on morphine-induced hyperactivity, reverse tolerance and postsynaptic dopamine receptor supersensitivity.lld:pubmed
pubmed-article:12009036pubmed:affiliationDepartment of Pharmacy, College of Pharmacy, Chungbuk National University, Cheongju, Korea.lld:pubmed
pubmed-article:12009036pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12009036pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed